查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016886

轉錄組學技術市場：按產品類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

Transcriptomics Technologies Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，轉錄組學技術市場價值將達到 83.9 億美元，到 2026 年將成長至 87.9 億美元，到 2032 年將達到 119.3 億美元，複合年成長率為 5.15%。

主要市場統計數據
基準年 2025 83.9億美元
預計年份：2026年 87.9億美元
預測年份 2032 119.3億美元
複合年成長率 (%) 5.15%

這是一本權威的入門書籍，它將現代轉錄組學技術定位為研究應用、臨床創新和產業戰略轉型的重要支柱。

轉錄組學處於分子層級洞察與轉化應用機會的交匯點，它正在改變研究人員、臨床醫生和產業創新者大規模、精準地分析基因表現的方式。定序平台、試劑化學和生物資訊學流程的進步，已將分析解析度從組織層面的簡介擴展到高解析度的單細胞水平，從而能夠提出關於新型生物標記和機制的假設，這些假設將直接促進藥物發現、臨床診斷和個人化醫療的發展。本書系統性地說明了影響產品開發、採購和轉化研究策略決策的技術、能力和相關人員的優先事項。

詳細概述了技術、營運和夥伴關係主導的變革，這些變革正在重新定義轉錄組學研究和應用領域的競爭力。

轉錄組學領域正經歷著一場變革浪潮，其驅動力來自於技術進步的融合、分析需求的不斷變化以及科研和臨床環境中操作重點的轉變。新型高通量平台和桌上型定序儀正在提升處理能力並縮短結果獲取時間。同時，試劑和樣品製備盒的化學性質也日趨穩定，從而能夠支持更廣泛的樣本類型並減少所需的起始樣本量。此外，高空間解析度的原位雜合反應技術在表達分析研究中重新煥發活力，它與基於定序的方法相輔相成，並拓展了生物學可觀察的邊界。

對美國將於 2025 年前實施的關稅政策如何重塑轉錄組學領域的採購、供應鏈和投資決策進行全面分析。

美國已宣布並於2025年前實施的關稅措施的累積影響，正在波及整個轉錄組學生態系統的籌資策略、供應商關係和供應鏈結構。進口設備和試劑關稅帶來的成本壓力，促使許多採購者重新評估採購慣例。採購團隊越來越關注供應商的來源、組件層面的風險以及總到岸成本，而不僅限於單價。因此，各機構正在實現供應商組合多元化，並探索利用區域供應商來降低貿易政策波動帶來的風險。

透過對產品、技術、應用和最終用戶進行詳細分析，揭示轉錄組學領域能力差距和價值創造的交匯點。

細分市場層面的趨勢揭示了每種產品類型、技術、應用和最終用戶群所面臨的不同機會和營運考量，這些因素應指南策略規劃和資源分配。就產品類型而言，本平台涵蓋桌上型定序儀和高通量定序儀，二者分別滿足不同的處理能力和性價比需求。桌上型儀器適用於分散式實驗室和診斷工作流程，因為這些場景對快速週轉和簡化的工作流程要求極高；而高通量定序儀則適用於大規模藥物研發專案和多樣檢體臨床研究，因為這些專案對單樣本成本和儀器處理能力要求極高。試劑和耗材包括 cDNA 合成試劑盒、RNA 萃取試劑盒和定序盒。每類產品都需滿足嚴格的品質和批間一致性要求，這些要求直接影響下游資料的完整性。軟體和服務包括資料分析軟體和資料管理服務，它們共同構成了一個可重複且可審計的流程基礎，該流程對於研究間的比較以及產生符合監管要求的證據至關重要。

美洲、歐洲、中東和非洲以及亞太地區的基礎設施、監管預期和部署路徑存在細微的區域差異。

區域趨勢正在影響轉錄組學領域的基礎設施投資、監管預期和夥伴關係機會，而對美洲、歐洲、中東和非洲以及亞太地區的深入了解對於有效進入市場至關重要。在美洲，成熟的研究機構和緊密的生物技術生態系統持續推動高通量定序和高階分析的需求。同時，臨床網路內的轉化醫學計畫和舉措醫療計畫也催生了對檢驗的工作流程和整合資料管理解決方案的需求。該地區還擁有大規模的試劑生產能力和充滿活力的供應商體系，這些都為技術的快速應用提供了支持。

在轉錄組學領域，平台、試劑和軟體提供者之間觀察到的清晰策略趨勢揭示了競爭差異化和夥伴關係模式的演變。

在轉錄組學生態系統中運作的公司正在推行差異化策略，以反映其在平台、試劑或軟體服務方面的核心優勢。這些策略選擇凸顯了未來的競爭格局和夥伴關係機會。平台供應商正致力於提升儀器的模組化、擴充性和易用性，以適應不同的實驗室環境並降低用戶採用門檻。那些能夠展現儀器在各種樣本類型中穩定性能，並能提供整合耗材生態系統的公司，相比那些尋求能夠最大限度降低技術風險的承包解決方案的客戶，擁有競爭優勢。

為產業領導者提供可操作的策略建議，以加強供應鏈韌性、加快部署速度，並使產品藍圖與應用主導的需求保持一致。

行業領導者應採取一系列切實可行的措施，以保持韌性並在不斷發展的轉錄組學領域中獲取價值。首先，他們應優先考慮供應商多元化和資質認證流程，該流程不僅評估價格和前置作業時間，還評估地域貿易政策風險、生產冗餘以及合格體系成熟度。投資關鍵試劑和耗材的雙源策略可以降低單點故障 (SPOF) 的風險，並增強採購談判中的議價能力。同時，符合法規和品質指標的供應商評分卡有助於快速合格。

我們要求對本報告中用於得出研究結果的混合研究途徑做出透明的解釋，該方法結合了對主要相關人員的訪談、技術三角驗證和供應鏈情境分析。

本研究採用混合方法，旨在捕捉影響轉錄組學應用的技術細節、營運動態和策略應對措施。主要資訊來源包括與學術界、受託研究機構(CRO)、醫院和診斷檢查室以及製藥和生物技術公司等相關人員的結構化訪談和專題討論，從而獲得有關採購重點、工作流程挑戰和驗證要求的第一手觀點。這些對話與二手研究（包括同行評審的科學文獻、行業白皮書、監管指導文件和供應商技術規範）進行交叉比對，以檢驗技術聲明和性能特徵。

這項簡明結論總結了整合解決方案、供應商韌性和資料管治對於不斷發展的轉錄組學領域取得成功的關鍵作用。

總之，轉錄組學技術正從小眾研究工具發展成為一項基礎性能力，推動廣泛的科學和臨床進步。平台、試劑和軟體的相互作用，正在建構一個需要整合解決方案和嚴格資料管治的環境，以充分發揮基因表現分析的轉化潛力。隨著應用範圍的擴大，相關人員必須在技術選擇上權衡通量、靈敏度和操作複雜性，同時將檢驗、可重複性和供應商穩定性作為核心優先事項。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：轉錄組學技術市場：依產品類型分類

  • 平台
    • 桌上型音序器
    • 高通量定序儀
  • 試劑和耗材
    • cDNA合成試劑盒
    • RNA萃取試劑盒
    • 定序盒
  • 軟體服務
    • 數據分析軟體
    • 資料管理服務

第9章：轉錄組學技術市場：依技術分類

  • 原位雜合反應
  • 次世代定序
  • 定量即時PCR

第10章 轉錄組學技術市場：依應用領域分類

  • 生物標記發現
  • 藥物發現與開發
  • 基因表現分析
    • 批量表達譜分析
    • 單細胞表現譜分析
  • 個人化醫療

第11章 轉錄組學技術市場：依最終使用者分類

  • 學術和研究機構
  • 合約研究機構
  • 醫院和診斷檢測機構
  • 製藥和生物技術公司

第12章 轉錄組學技術市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 轉錄組學技術市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 轉錄組學技術市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國轉錄組學技術市場

第16章：中國轉錄組學技術市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 10x Genomics, Inc.
  • Agilent Technologies, Inc.
  • Akoya Biosciences, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Bruker Corporation
  • Carl Zeiss AG
  • Fluidigm Corporation
  • Illumina, Inc.
  • Oxford Nanopore Technologies Limited
  • Pacific Biosciences of California, Inc.
  • QIAGEN NV
  • Roche Holding AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-031685195774

The Transcriptomics Technologies Market was valued at USD 8.39 billion in 2025 and is projected to grow to USD 8.79 billion in 2026, with a CAGR of 5.15%, reaching USD 11.93 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.39 billion
Estimated Year [2026] USD 8.79 billion
Forecast Year [2032] USD 11.93 billion
CAGR (%) 5.15%

An authoritative introduction that situates modern transcriptomics technologies as transformative pillars for research translation, clinical innovation, and industrial strategy

Transcriptomics stands at the intersection of molecular insight and translational opportunity, transforming how researchers, clinicians, and industry innovators interrogate gene expression at scale and with precision. Advances in sequencing platforms, reagent chemistry, and bioinformatic pipelines have expanded analytical resolution from bulk tissue snapshots to high-resolution single-cell landscapes, enabling new classes of biomarkers and mechanistic hypotheses that directly inform drug discovery, clinical diagnostics, and personalized medicine. This introduction frames the technologies, capabilities, and stakeholder priorities that shape strategic decisions across product development, procurement, and translational research.

Over recent years, technological maturation has reduced many historic barriers to entry while simultaneously raising the bar for data quality and reproducibility. As platforms deliver higher throughput and reagents evolve to preserve sample integrity under diverse workflows, investigators must balance cost, turnaround, and analytic fidelity. Meanwhile, software and data management services are evolving from auxiliary tools to mission-critical infrastructure that underpins regulatory compliance, cross-study integration, and collaboration. Together, these dynamics compel organizations to reassess investment priorities, partnerships, and operational models to stay competitive and translationally relevant.

In this context, stakeholders must navigate complex trade-offs among platform performance, reagent robustness, and software capabilities, and align those choices with application-specific needs such as biomarker discovery, gene expression profiling, and drug development. The subsequent sections offer a focused synthesis of transformative market shifts, policy impacts, segmentation intelligence, regional nuances, company strategies, and practical recommendations designed to inform strategic planning and operational execution in the evolving transcriptomics landscape.

A detailed synthesis of the technological, operational, and partnership-driven shifts that are redefining competitiveness in transcriptomics research and applications

The transcriptomics landscape is undergoing a wave of transformative shifts driven by converging technological advances, evolving analytical expectations, and changing operational priorities within research and clinical environments. Newer high-throughput platforms and benchtop sequencers are expanding capacity and reducing time-to-result, while reagent chemistries and library preparation kits have become more robust, enabling broader sample types and reduced input requirements. Concurrently, in situ hybridization techniques are experiencing renewed interest for spatially resolved expression studies, complementing sequencing-based approaches and pushing the boundaries of what is biologically observable.

At the same time, data analysis software and data management services are gaining prominence as essential enablers of reproducible science. Workflow standardization, cloud-native pipelines, and integrated laboratory informatics are facilitating cross-institutional studies and longitudinal data aggregation. These software capabilities are also catalyzing collaborations across academia, contract research organizations, and biopharma, where harmonized data processing becomes a prerequisite for multi-center trials and regulatory submissions. In addition, an increasing emphasis on single-cell expression profiling is reshaping reagent demand and sequencing throughput requirements, necessitating combined investments in specialized kits and high-throughput sequencers to meet experimental complexity.

Strategic partnerships and vertical integration are emerging as competitive levers. Platform providers collaborating with reagent suppliers and analytics firms can offer more cohesive solutions that reduce adoption friction. Moreover, end users are demonstrating a preference for turnkey offerings that lower internal operational overhead while guaranteeing quality. These shifts collectively signal a move from component-based procurement toward solution-oriented engagements, reshaping supplier selection criteria and shaping the future of transcriptomics deployment across research and clinical settings.

A comprehensive analysis of how United States tariff policies implemented through 2025 are reshaping procurement, supply chains, and investment decisions in transcriptomics

The cumulative effects of United States tariffs announced and implemented through 2025 are influencing procurement strategies, supplier relationships, and supply chain configurations across the transcriptomics ecosystem. Tariff-driven cost pressures on imported equipment and reagents have prompted many buyers to re-evaluate sourcing practices, with procurement teams increasingly scrutinizing supplier origins, component-level exposures, and total landed cost rather than focusing solely on unit price. As a result, organizations are pursuing diversified supplier portfolios and exploring regional vendors to mitigate exposure to trade policy volatility.

In addition to direct cost implications, tariffs have altered the cadence of capital investment decisions for sequencing platforms. Institutions that previously planned multi-year upgrade cycles are now factoring potential customs duties and longer lead times into financing models, which can delay adoption of next-generation instruments. To manage these risks, a number of research organizations and larger commercial buyers are negotiating longer-term agreements with suppliers, including service contracts and bundled reagent commitments, to stabilize pricing and guarantee spare parts availability despite tariff-induced market uncertainty.

Tariffs have also accelerated conversations about nearshoring and contract manufacturing for critical reagents and consumables. Stakeholders recognize that relocating production or qualifying secondary manufacturing sites can shorten supply chains and reduce tariff exposure, but such shifts require investment in quality systems and regulatory validation that can extend timelines. Concurrently, software and data services, which are less tariff-exposed, have gained increased strategic importance as organizations seek to optimize existing hardware utilization and extract more value from legacy platforms. Overall, trade policy changes in 2025 have reinforced the need for flexible procurement strategies, strengthened supplier relationships, and a greater emphasis on supply chain transparency within transcriptomics operations.

An insightful breakdown of product, technological, application, and end-user segmentation that clarifies where capability gaps and value creation converge in transcriptomics

Segment-level dynamics reveal differentiated opportunities and operational considerations across product type, technology, application, and end-user segments that should inform strategic planning and resource allocation. Within product type, platforms encompass both benchtop sequencers and high-throughput sequencers, each catering to distinct throughput and throughput-cost trade-offs. Benchtop instruments are attractive for decentralized laboratories and diagnostic workflows that value rapid turnaround and simplified workflows, whereas high-throughput sequencers serve large-scale discovery programs and multi-sample clinical studies where cost per sample and instrument capacity are paramount. Reagents and consumables include cDNA synthesis kits, RNA extraction kits, and sequencing kits, with each category subject to stringent quality and lot-to-lot consistency requirements that directly influence downstream data integrity. Software and services cover data analysis software and data management services, which together form the backbone of reproducible, auditable pipelines required for cross-study comparisons and regulatory-grade evidence generation.

Across technologies, in situ hybridization offers spatial context that complements sequencing-based approaches, next generation sequencing provides breadth and depth for comprehensive transcriptome profiling, and quantitative real time PCR remains a workhorse for targeted validation and routine quantitation. These technologies serve distinct scientific questions and operational constraints, and they often coexist within the same programs to provide orthogonal validation and complementary insights. Regarding applications, stakeholders are deploying transcriptomics in biomarker discovery, drug discovery and development, gene expression profiling, and personalized medicine, where gene expression profiling itself spans bulk expression profiling and single-cell expression profiling. Bulk approaches remain relevant for tissue-level signals and established workflows, whereas single-cell profiling is unlocking cell-type specific expression patterns that reveal heterogeneity and rare cell populations.

Finally, end-user segmentation includes academic and research institutes, contract research organizations, hospitals and diagnostic laboratories, and pharmaceutical and biotechnology companies. Academic and research institutions continue to drive methodological innovation and exploratory studies, contract research organizations are scaling services to meet industry demand for outsourced expertise, hospitals and diagnostic labs are focused on clinical-grade workflows and compliance, and pharmaceutical and biotech firms prioritize throughput, standardization, and integration with discovery-to-clinic pipelines. Each segment exhibits unique purchasing cycles, quality expectations, and partnership models, and aligning product strategies with these differentiated requirements is essential for sustained commercial relevance.

A regionally nuanced perspective on infrastructure, regulatory expectations, and adoption pathways across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape infrastructure investments, regulatory expectations, and partnership opportunities across the transcriptomics domain, and a nuanced understanding of the Americas, Europe, Middle East & Africa, and Asia-Pacific is critical for effective market engagement. In the Americas, established research institutions and a dense biotechnology ecosystem continue to drive demand for high-throughput sequencing and advanced analytics, while translational initiatives and precision medicine programs in clinical networks create demand for validated workflows and integrated data management solutions. This region also houses significant reagent manufacturing capacity and a vibrant vendor landscape that supports rapid technology adoption.

Europe, Middle East & Africa presents a heterogeneous environment where strong regulatory frameworks in some European markets coexist with emerging clinical and research investments across the Middle East and Africa. In these markets, demand often centers on reproducibility, data protection compliance, and interoperability with national health infrastructures, creating an emphasis on certified workflows, local validation, and partnerships with regional service providers. Research consortia and collaborative networks in Europe also foster standardized protocols and cross-border data sharing, increasing the value of interoperable software and governance-ready data management services.

Asia-Pacific continues to exhibit rapid expansion of sequencing capacity, investment in local reagent manufacturing, and growing adoption of single-cell and spatial methods in both academic centers and industrial R&D. Many governments in the region are prioritizing biotech innovation, which accelerates translational collaborations and creates opportunities for suppliers who can support scale, localization of supply chains, and regulatory alignment. Across all regions, an emerging commonality is the prioritization of data integrity, workflow reproducibility, and supplier transparency, which together influence procurement decisions and partnership development.

Clear strategic patterns among platform, reagent, and software providers that reveal how competitive differentiation and partnership models are evolving within transcriptomics

Companies operating in the transcriptomics ecosystem are pursuing differentiated strategies that reflect their core competencies in platforms, reagents, or software and services, and these strategic choices illuminate likely competitive trajectories and partnership opportunities. Platform vendors are investing in instrument modularity, throughput scalability, and ease of use to address diverse laboratory footprints and reduce barriers to adoption. Firms that can demonstrate robust instrument performance across varied sample types and provide integrated consumable ecosystems gain an advantage with customers seeking turnkey solutions that minimize technical risk.

Reagent manufacturers are prioritizing lot consistency, robust supply chains, and compatibility across commonly used platforms. Given the sensitivity of downstream analyses to sample preparation, suppliers who can certify cross-platform compatibility and offer validated workflows for both bulk and single-cell profiling increase their appeal to translational and clinical customers. In parallel, providers of data analysis software and data management services are differentiating themselves through cloud-native architectures, compliance-ready features, and analytics accelerators that reduce time-to-insight. These companies are forging alliances with instrument and reagent suppliers to deliver bundled solutions that streamline onboarding and maintain data provenance.

Across the competitive landscape, value is accruing to organizations that combine technical excellence with service-oriented delivery models, including training, validation support, and long-term reagent availability commitments. Strategic M&A and partnership activity has centered on filling capability gaps-such as combining spatial technologies with sequencing workflows or integrating advanced analytics with laboratory informatics-to provide more complete offerings. For stakeholders evaluating potential partners or acquisition targets, emphasis should be placed on demonstrated quality control systems, regulatory readiness, and the ability to scale production and support international deployments.

Actionable, strategic recommendations for industry leaders to strengthen supply resilience, accelerate adoption, and align product roadmaps with application-driven demand

Industry leaders should adopt a set of pragmatic, actionable measures to maintain resilience and capture value as the transcriptomics landscape evolves. First, prioritize supplier diversification and qualification processes that assess not only price and lead times but also geographic exposure to trade policy risks, manufacturing redundancy, and quality system maturity. Investing in dual-source strategies for critical reagents and consumables reduces single-point-of-failure risk and provides leverage during procurement negotiations, while supplier scorecards aligned to regulatory and quality metrics facilitate faster qualification.

Second, pursue vertically integrated partnerships or bundled solution agreements that align platform performance with validated reagent kits and analytics pipelines. Such integrations lower adoption friction for end users and create stickier commercial relationships. When negotiating, include provisions for service-level agreements, reagent continuity, and data interoperability standards to protect operational continuity. Third, accelerate investments in data management and analytic infrastructure that enable reproducible pipelines and compliance-ready evidence generation. Cloud-first architectures, standardized pipelines, and audit-ready data governance will increasingly distinguish best-in-class deployments.

Fourth, align product roadmaps with application-specific needs such as single-cell profiling and spatial transcriptomics by offering validated end-to-end workflows that reduce the time and expertise required to generate actionable insights. Finally, incorporate tariff scenario planning and supply chain stress-testing into capital expenditure and procurement planning. Prepare contingency playbooks that include nearshoring options, buffer inventory strategies, and contract terms that mitigate the operational impact of trade policy shifts. Together, these actions will help organizations reduce risk, accelerate adoption, and sustain competitive differentiation.

A transparent explanation of the mixed-method research approach combining primary stakeholder interviews, technical triangulation, and supply chain scenario analysis used to derive the report's insights

This research draws on a mixed-method approach designed to capture the technological nuances, operational dynamics, and strategic responses shaping transcriptomics adoption. Primary inputs include structured interviews and targeted consultations with stakeholders across academia, contract research organizations, hospitals and diagnostic laboratories, and pharmaceutical and biotechnology companies, providing first-hand perspectives on procurement priorities, workflow pain points, and validation requirements. These conversations have been triangulated with secondary research encompassing peer-reviewed scientific literature, industry white papers, regulatory guidance documents, and supplier technical specifications to verify technological claims and performance characteristics.

Analytical steps included comparative capability mapping of platforms, reagents, and software offerings against application requirements such as throughput, sensitivity, and data interoperability. Supply chain analysis examined supplier footprints, manufacturing locations for critical consumables, and service network density to assess exposure to trade policy and logistics risk. The research also incorporated scenario analysis to explore the operational implications of tariff changes and supply chain disruptions, focusing on procurement strategies, inventory management, and potential nearshoring pathways.

Quality assurance measures included cross-validation of supplier claims with independent third-party evaluations where available, and consistency checks against documented regulatory submissions and validation studies. Limitations of the methodology are acknowledged; where empirical data are sparse, findings rely on expert consensus and documented vendor specifications, and readers are advised to supplement this report with primary technical validation in the context of specific laboratory workflows. Overall, the methodology blends qualitative insight with technical evaluation to produce actionable intelligence for decision-makers.

A concise conclusion synthesizing how integrated solutions, supplier resilience, and data governance will determine success in the evolving transcriptomics landscape

In conclusion, transcriptomics technologies are transitioning from niche research tools to foundational capabilities that enable a broad spectrum of scientific and clinical advances. The interplay among platforms, reagents, and software is creating an environment in which integrated solutions and disciplined data governance are essential to realize the full translational potential of gene expression profiling. As adoption expands, stakeholders must navigate technological choices that balance throughput, sensitivity, and operational complexity while ensuring that validation, reproducibility, and supplier resilience remain core priorities.

Trade policy shifts and tariff dynamics have underscored the importance of supply chain transparency and diversified sourcing strategies, prompting organizations to incorporate procurement resilience into long-term planning. Regionally differentiated adoption patterns further highlight the need for localization strategies-from regulatory-aligned offerings in Europe, Middle East & Africa to scale and manufacturing localization in Asia-Pacific and high-throughput deployments in the Americas. Lastly, companies that can deliver validated end-to-end workflows, shorten time-to-insight through advanced analytics, and mitigate operational risks through robust service models will capture disproportionate value as the field matures.

Decision-makers should therefore focus on building flexible supplier partnerships, investing in compliance-ready data infrastructure, and aligning product and service offerings to application-driven needs. By doing so, organizations will be positioned to accelerate discovery, improve clinical translation, and sustain competitive advantage in the rapidly evolving transcriptomics landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transcriptomics Technologies Market, by Product Type

  • 8.1. Platforms
    • 8.1.1. Benchtop Sequencers
    • 8.1.2. High Throughput Sequencers
  • 8.2. Reagents & Consumables
    • 8.2.1. cDNA Synthesis Kits
    • 8.2.2. RNA Extraction Kits
    • 8.2.3. Sequencing Kits
  • 8.3. Software & Services
    • 8.3.1. Data Analysis Software
    • 8.3.2. Data Management Services

9. Transcriptomics Technologies Market, by Technology

  • 9.1. In Situ Hybridization
  • 9.2. Next Generation Sequencing
  • 9.3. Quantitative Real Time PCR

10. Transcriptomics Technologies Market, by Application

  • 10.1. Biomarker Discovery
  • 10.2. Drug Discovery & Development
  • 10.3. Gene Expression Profiling
    • 10.3.1. Bulk Expression Profiling
    • 10.3.2. Single Cell Expression Profiling
  • 10.4. Personalized Medicine

11. Transcriptomics Technologies Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals & Diagnostic Laboratories
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Transcriptomics Technologies Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Transcriptomics Technologies Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Transcriptomics Technologies Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Transcriptomics Technologies Market

16. China Transcriptomics Technologies Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 10x Genomics, Inc.
  • 17.6. Agilent Technologies, Inc.
  • 17.7. Akoya Biosciences, Inc.
  • 17.8. Becton, Dickinson and Company
  • 17.9. Bio-Rad Laboratories, Inc.
  • 17.10. Bio-Techne Corporation
  • 17.11. Bruker Corporation
  • 17.12. Carl Zeiss AG
  • 17.13. Fluidigm Corporation
  • 17.14. Illumina, Inc.
  • 17.15. Oxford Nanopore Technologies Limited
  • 17.16. Pacific Biosciences of California, Inc.
  • 17.17. QIAGEN N.V.
  • 17.18. Roche Holding AG
  • 17.19. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BENCHTOP SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BENCHTOP SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BENCHTOP SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY HIGH THROUGHPUT SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY CDNA SYNTHESIS KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY CDNA SYNTHESIS KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY CDNA SYNTHESIS KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY RNA EXTRACTION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY RNA EXTRACTION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY RNA EXTRACTION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SEQUENCING KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SEQUENCING KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SEQUENCING KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY QUANTITATIVE REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY QUANTITATIVE REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY QUANTITATIVE REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BULK EXPRESSION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BULK EXPRESSION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY BULK EXPRESSION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SINGLE CELL EXPRESSION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SINGLE CELL EXPRESSION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SINGLE CELL EXPRESSION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 165. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 166. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 167. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 170. GCC TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 192. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 193. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 194. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 197. G7 TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 201. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 202. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 203. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 206. NATO TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA TRANSCRIPTOMICS TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)